Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | hexokinase type 2 | 0.0963 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0963 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.0963 | 1 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0047 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0047 | 0 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0963 | 1 | 1 |
Plasmodium vivax | hexokinase, putative | 0.0963 | 1 | 1 |
Brugia malayi | hexokinase type II | 0.0306 | 0.2826 | 0.1977 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.013 | 0.0899 | 0.0192 |
Loa Loa (eye worm) | hypothetical protein | 0.0306 | 0.2826 | 0.2696 |
Onchocerca volvulus | Hexokinase homolog | 0.0604 | 0.608 | 0.5819 |
Leishmania major | DNA topoisomerase ii | 0.013 | 0.0899 | 0.0192 |
Brugia malayi | Hexokinase family protein | 0.0963 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0097 | 0.0539 | 0.0367 |
Echinococcus granulosus | hexokinase | 0.0963 | 1 | 1 |
Onchocerca volvulus | 0.0963 | 1 | 1 | |
Leishmania major | hexokinase, putative | 0.0963 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0298 | 0.2736 | 0.1877 |
Trypanosoma brucei | hexokinase, putative | 0.0963 | 1 | 1 |
Entamoeba histolytica | hexokinase 1 | 0.0963 | 1 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0138 | 0.0988 | 0.5 |
Onchocerca volvulus | 0.0963 | 1 | 1 | |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0963 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0963 | 1 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.013 | 0.0899 | 0.0192 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0144 | 0.1057 | 0.0895 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0144 | 0.1057 | 0.1057 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.013 | 0.0899 | 0.0192 |
Echinococcus multilocularis | hexokinase | 0.0963 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0963 | 1 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0144 | 0.1057 | 0.5 |
Schistosoma mansoni | hexokinase | 0.0963 | 1 | 1 |
Onchocerca volvulus | 0.0963 | 1 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0306 | 0.2826 | 0.2696 |
Treponema pallidum | hexokinase (hxk) | 0.0963 | 1 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0078 | 0.0337 | 1 |
Brugia malayi | Hexokinase family protein | 0.0604 | 0.608 | 0.5617 |
Trypanosoma brucei | hexokinase | 0.0963 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0963 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.0963 | 1 | 1 |
Onchocerca volvulus | 0.0604 | 0.608 | 0.5819 | |
Loa Loa (eye worm) | hypothetical protein | 0.0657 | 0.6656 | 0.6595 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.013 | 0.0899 | 0.0192 |
Echinococcus granulosus | hexokinase | 0.0963 | 1 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0144 | 0.1057 | 0.1057 |
Plasmodium falciparum | hexokinase | 0.0963 | 1 | 1 |
Echinococcus granulosus | hexokinase type 2 | 0.0963 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.0963 | 1 | 1 |
Entamoeba histolytica | hexokinase 2 | 0.0963 | 1 | 1 |
Loa Loa (eye worm) | hexokinase type II | 0.0963 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0298 | 0.2736 | 0.2604 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0144 | 0.1057 | 0.1057 |
Loa Loa (eye worm) | hypothetical protein | 0.0097 | 0.0539 | 0.0367 |
Loa Loa (eye worm) | hexokinase | 0.0604 | 0.608 | 0.6009 |
Loa Loa (eye worm) | hexokinase | 0.0963 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 28.2 % | Cytotoxicity against human IMR32 cells at 60 ug/ml by MTT assay | ChEMBL. | 18456372 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.